Wednesday, June 27, 2018

Poliovirus Therapy for Recurrent Glioblastoma Has 3-Year Survival Rate of 21%

A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, with a three-year survival rate of 21 percent in a phase 1 clinical trial. Comparatively, just 4 percent of patients at Duke with the same type of recurring brain tumors were alive at three years when undergoing the previously available standard treatment.Continue Reading